leadf
logo-loader
viewLexaGene Holdings Inc.

 LexaGene announces appointment of Dr Shelley Rankin to its Scientific Advisory Board; CEO delivers video message

Dr Rankin is a Professor of Microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet) and is the Chief of Clinical Microbiology and Head of Diagnostic Services at Penn Vet’s Ryan Hospital

LexaGene Holdings Inc. -
LexaGene also announced that its founder and CEO, Dr Jack Regan has delivered a video message on the company’s progress towards commercial sales

 LexaGene Holdings, Inc. (CVE:LXG) (OTCQB:LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has announced the appointment of Dr Shelley Rankin to its Scientific Advisory Board.

Dr Rankin is a Professor of Microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet) and is the Chief of Clinical Microbiology and Head of Diagnostic Services at Penn Vet’s Ryan Hospital.

READ: LexaGene Holdings closes on C$13.29M in financing to build inventory and expand sales

She is a member of many scientific societies, a past Chair of the American Society for Microbiology, Animal Health Division (2011) and is currently Co-Chair of the Subcommittee on Salmonella for the United States Animal Health Association.

Dr Rankinis an author of the International Society for Companion Animal Infectious Diseases (ISCAID) Guidelines for Antimicrobial Use to treat infections of the skin, urinary tract, and respiratory tract. She has published 100 peer-reviewed papers and regularly speaks at international conferences. 

In a statement regarding the appointment, Dr Jack Regan, LexaGene’s founder and CEO commented: “As we approach sales, I’m very pleased to add Dr. Rankin to our Scientific Advisory Board. She is an outspoken key opinion leader in veterinary medicine and is constantly advocating for high-quality diagnostics for veterinarians in order to promote better animal health and antibiotic stewardship. We look forward to working with her to help meet the needs of veterinarians worldwide.”

LexaGene also announced that Dr Regan has delivered a video message on the company’s progress towards commercial sales. The message and a demonstration of the group's MiQLab can be viewed on the corporate website here: https://lexagene.com/video-message-to-investors/

Contact the author at [email protected]

Quick facts: LexaGene Holdings Inc.

Price: 0.7 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $79.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of LexaGene Holdings Inc. named herein, including the promotion by the Company of LexaGene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

LexaGene hires two salespeople to tackle diagnostic and vet market with new...

LexaGene (CVE: LXG-OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company has made two key sales hires as they look to begin to roll out their genetic analyzers for rapid pathogen detection called MiQLab. Regan says they are hiring in the...

on 07/14/2020

2 min read